Lifeward shares surge 21.07% intraday after Humana approves ReWalk 7 reimbursement coverage.

Lifeward surged 21.07% intraday after announcing prior authorization approval for its ReWalk 7 exoskeleton from Humana Medicare Advantage Plan, the second-largest U.S. Medicare Advantage provider. This follows a similar approval from UnitedHealthcare in November, collectively covering 47% of Medicare Advantage enrollees. The approvals enhance access to the exoskeleton for spinal cord injury patients and are expected to strengthen Lifeward’s revenue and cash flow dynamics, as highlighted by CEO Mark Grant. The news directly addresses reimbursement scalability, a critical factor for market expansion, aligning with the stock’s sharp intraday rally.